AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

Core Points - Richard A. Gonzalez will retire from AbbVie's board of directors effective July 1, 2025, and Robert A. Michael will assume the role of chairman [1] - Roxanne S. Austin expressed gratitude for Gonzalez's leadership and confidence in Michael's ability to guide AbbVie into its next growth phase [2] - Michael acknowledged Gonzalez's exceptional leadership and emphasized his commitment to AbbVie's success and impact on patients and shareholders [2] - Glenn F. Tilton will also retire from AbbVie's board effective July 1, 2025, after serving as lead independent director from 2013 to 2024 [2] About Robert A. Michael - Robert A. Michael has been appointed as chairman and is currently the CEO of AbbVie, with a history of leadership roles within the company [3] - He has over 32 years of experience in various sectors, including pharmaceuticals and diagnostics, and has played a key role in AbbVie's strategic development [3] - Michael's previous positions include president and chief operating officer, vice chairman, and chief financial officer, showcasing his extensive experience in corporate operations [3] About AbbVie - AbbVie aims to discover and deliver innovative medicines addressing serious health issues across key therapeutic areas such as immunology, oncology, and neuroscience [4] - The company is committed to making a significant impact on people's lives through its diverse product offerings, including those in the Allergan Aesthetics portfolio [4]